{
    "title": "US FDA declines to approve Regeneron's higher-dose Eylea, shares tumble",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12239957/US-FDA-declines-approve-Regeneron-high-dose-Eylea.html",
    "date": "2023-06-27",
    "keywords": [
        "drug",
        "eylea",
        "version",
        "regeneron",
        "treatment",
        "letter",
        "year",
        "khushi",
        "mandowara",
        "cause",
        "blindness",
        "response",
        "filler",
        "safety",
        "eye",
        "june",
        "health",
        "tuesday",
        "disease",
        "company",
        "setback",
        "effort",
        "blockbuster",
        "food",
        "administration",
        "agency",
        "application",
        "review",
        "inspection",
        "fda",
        "thirdparty",
        "dose",
        "efficacy",
        "trial",
        "design",
        "labeling",
        "substance",
        "manufacturing",
        "study",
        "analyst",
        "robyn",
        "karnauskas",
        "compliance",
        "issue",
        "delay",
        "vabysmo",
        "wet",
        "degeneration",
        "amd",
        "macular",
        "edema",
        "approval",
        "gap",
        "latestage",
        "competition",
        "reporting",
        "raghav",
        "mahobe",
        "bengaluru",
        "editing",
        "krishna",
        "chandra",
        "eluri",
        "maju",
        "samuel",
        "sriraj",
        "kalluvila",
        "david",
        "gregorio"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}